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SUMMARY 
Classical QSAR began almost 30 years ago. This article briefly traces its development, use and impact in 
relation to drug design and medicinal chemistry. Particular aspects discussed include hydrophobicity, rela- 
tive potency in a series, tissue selectivity, central nervous system penetration, pharmacokinetics, potency 
optimization, bioisosterism, mechanistic insights, synthesis termination, receptor mapping, and the design of 
marketed drugs and late-stage drug candidates. In addition, some recent QSAR studies and examples of the 
use of the Free-Wilson approach are reviewed. 
INTRODUCTION 
The field of classical Quantitative Structure-Activity Relationships (QSARs) as we know it 
today began with the seminal work of Hansch and Fujita [1], published in 1964, which related 
biological activity for members of a congeneric series with substituent parameters representing 
hydrophobic, electronic and steric effects by means of an equation now known as the Hansch 
equation: 
log (I/C) = arc - brt 2 + c~ + dEs + k (1) 
or 
log (1/C) = a logP - b (logP) 2 + co + dE~ + k (2) 
where C is the concentration of  a compound which produces a standard biological response, 17 is 
a hydrophobic substituent constant derived from partition coefficient data, o is the Hammett 
electronic substituent constant, E~ is the Taft steric substituent constant and P is the octanol -1/  
water partition coefficient. 
Prior to this, medicinal chemists considered structure-activity relationships only in qualitative 
descriptive terms and hydrophobicity received little attention. The breakthrough provided by the 
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work of Hansch and Fujita which progressively brought about a pronounced change in the 
thinking about structure-activity relationships, was (i) the recognition of the impact of hydropho- 
bicity and its quantitative expression in substituent parameter form and (ii) the concept that a 
combination of hydrophobic, electronic and steric effects would control activity and that their 
relative contributions could be determined by multiple regression analysis of a dataset from a 
congeneric series. 
Also in 1964, the Free-Wilson method [2] was published and subsequently modified by Fujita 
and Ban [3] to the form in which it is now generally used. Later a hybrid Hansch/Free-Wilson 
method was formalized by Kubinyi [4] and nonstatistical methods were introduced by Topliss 
[5,6]. A detailed review of these methods and their origins is beyond the scope of this article, but 
excellent detailed accounts have been published [%9]. 
IMPACT OF QSAR 
Over the three decades following the birth of QSAR its concepts have been validated through 
the establishment of literally thousands of equations, accounting satisfactorily for quantitative 
relative activity in a series of compounds in terms of readily understandable physicochemical 
phenomena. This has been done across an immense variety of biological systems and compound 
types and has led to marked advances in medicinal chemistry and drug design [10]. It has also 
been used quite extensively in the agrochemical and environmental toxicology fields. 
QSAR represents an important stage in the development of our understanding of the funda- 
mentals of the processes and factors controlling drug action, including the role of hydrophobicity 
[11], and has provided many useful insights for drug design [12]. Many successful activity predic- 
tions have been made from QSAR equations [13,14], often leading to the identification of com- 
pounds with increased potency. QSAR equations have provided direction for improving selectiv- 
ity of action and deciding when to terminate a compound series. Through QSAR-based series 
design more information per compound synthesized can be obtained, thus leading to increased 
efficiency [13]. A new characterization of bioisosterism using QSAR has broadened the use of this 
principle and its utility in drug design. Also, QSAR results have contributed to our understanding 
of the mechanism of action of drugs and provided information on the nature of enzyme-ligand 
and drug receptor binding sites. A discussion of these various aspects follows. 
HYDROPHOBICITY IN A QSAR CONTEXT 
Prior to 1964, an appreciation of the magnitude of the role of hydrophobicity in drug action 
in SAR studies by medicinal chemists was quite limited. For example, a chloro substituent 
was usually thought of exclusively in terms of its electron-withdrawing properties and it was not 
until the advent of QSAR that its hydrophobic properties were adequately considered. 
The importance of hydrophobicity in controlling drug action is illustrated by Table 1, which was 
compiled from a collection of some 98 QSAR equations, evenly divided between in vitro and 
in vivo examples, taken from Reference 10. The hydrophobic parameter is the major variable in 
ca. two thirds of the in vivo cases and over 40% of the in vitro examples. Also, Hansch has 
reported [15] that in a database of some 3000 biological QSARs only 15% lack a term for 
hydrophobicity. 
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Accounting for relative potency in a series 
Accounting for relative potency in a series is illustrated by some recent publications on 
5-1ipoxygenase inhibitors. Summers et al. [16] found that for a series of 111 structurally diverse 
hydroxamic acids of general structure (1) the predominant property determining the inhibitory 
potency is the hydrophobicity of the molecule. Hydrophobicity in this compound series spans 
seven log units and compound potencies differ by more than tour orders of magnitude. Based on 
the hydrophobic parameter coefficient of 0.57 it was concluded that these compounds appear to 
be partially desolvated on binding to 5-1ipoxygenase (a slope of one indicates complete desolva- 
tion) which suggests [17] that the inhibitor rests upon a surface or shallow trough of the enzyme. 
This also illustrates how QSAR can provide insight into the nature of enzyme-ligand sites. 
A similar case was reported by Hammond et al. [18] for a series of some fifty 4- and 6- 
substituted 2,3-dihydro-5-benzofuranol 5-1ipoxygenase inhibitors (2) where a linear dependence 
of log ICs0 on log P extends over three orders of magnitude in biological activity and five orders 
of magnitude in partition coefficient. 
A third study by Hlasta et al. [19] on a series of 1-phenyl-3-pyrazolidinones and related 
tetrahydropyridazinones (3) showed a relationship of increased 5-1ipoxygenase inhibitory poten- 
cy with an increase in log P and an N-phenyl electronic effect as measured by a ~3C NMR chemical 
shift parameter, e.g. Eq. 3: 
pICs0 = 0.90 (_+ 0.19) log P + 0.15 (+ 0.06) C NMR 1 - 24.19 (+ 8.67) 
n = 21, r 2 = 0.79, s = 0.49, F (2,18) = 33.6, p = 0.001 
(3) 
Independently, log P explains about 70% of the pICs0 data variance, thus making hydrophobicity 
TABLE 1 
PARAMETER FREQUENCY IN REGRESSION EQUATIONS 
Parameter In vitro frequency (%) In vivo frequency (%) 
Total Major vat. Sole var. Total Major var. Sole var. 
Hydrophobic (all) 69 




42 16 88 64 29 
63 
27 8 57 18 0 
15 6 24 6 2 
4 4 18 6 4 
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the dominant parameter controlling relative activity as in the other two series of lipoxygenase 
inhibitors. 
Tissue selectivity 
An example of the relationship of hydrophobicity to tissue selectivity is provided in a recent 
study by Roth et al. [20] on a series of HMG-CoA reductase inhibitors which are an important 
class of drugs for lowering plasma total and LDL-cholesterol in hypercholesterolemic patients. It 
has been proposed [21] that the side effects of these drugs may be reduced by confining their 
action to the liver and that tissue selectivity is dependent on hydrophobicity with the more 
hydrophilic compounds showing higher liver selectivity. This hypothesis was tested by comparing 
a set of 15 potent substructurally diverse inhibitors encompassing a broad range of calculated 
hydrophobicity (C LOGP) for their ability to inhibit sterol synthesis in tissue cubes derived from 
rat liver, spleen and testis. A linear relationship was found between tissue/liver ratios and log P as 
expressed in Eqs. 4 and 5: 
log (ICs0 spleen/liver) = 0.93 - 0.52 C LOGP 
n = 14, r 2 = 0.62, s = 0.65, F = 21.6 (p < 0.001) 
(4) 
log (ICs0 testis/liver) = 1.17 - 0.65 C LOGP 
n = 15, r 2 = 0.67, s = 0.75, F = 26.2 (p < 0.001) 
(5) 
Although about one third of the data variance is not accounted for in both of these equations, 
suggesting that factors other than hydrophobicity related to differences between the compounds 
are also involved, there is, nevertheless, a strong statistical correlation between tissue selectivity 
and log P. These equations show that at C LOGP = 2 there is no selectivity between liver and the 
other tissues. Below a C LOGP of 2 the compounds are increasingly liver selective as they become 
more hydrophilic; above a C LOGP of 2 selectivity for testis and spleen increases with increasing 
hydrophobicity. Since intrinsic potency differences amongst the inhibitors were minimal, it was 
concluded that tissue selectivity was highly dependent on the ability of peripheral tissues to 
discriminate between compounds on the basis of hydrophobicity. 
Central nervous system penetration 
An early result from the QSAR studies of Hansch was the finding [22] that maximum potency 
in 16 sets of hypnotics was obtained for compounds with a log P value (log Po) of around 2. This 
was associated with transport properties and penetration of the blood brain barrier by passive 
diffusion, controlled by the hydrophobicity of the compounds. The implications for drug design 
were quickly noted both for CNS agents and for avoidance of CNS side effects in other types of 
drugs. The general concept of a log Po optimum of 2 for CNS penetration was supported by later 
findings on anesthetics [23], benzodiazepines [24] and centrally acting antihypertensive agents 
[25]. However, it was also recognized that some small hydrophilic molecules use an active trans- 
port process and that molecular size can have a significant negative effect for MW > 500 [26]. 
In 1987 Hansch etal. reported [27] on studies covering the partition coefficients of a wide range 
of clinically used CNS drugs, including barbiturates, benzodiazepines, antipsychotics, antidepres- 
sants and other miscellaneous types. These generally fell into a range of 1.5-2.5 when measured 
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at pH 7.4 (distribution coefficient), consistent with the earlier concept. Although there were some 
significant outliers, suboptimal CNS penetration can be compensated for by a larger dose. It 
appears that charged molecules which are large and hydrophobic can passively diffuse through 
the blood brain barrier. Usually the presence of such a charge is thought to preclude passage 
through this barrier. 
Avoidance or marked reduction of CNS effects should in principle be achievable with log P 
values outside the range 1.0-3.0, based on the paraboliC relationship of CNS entry and log P. A 
variety of antihistamines were examined in this context [27] and it was observed that the non- 
sedating antihistamines had log P values at pH 7.4 well outside this range, in c0nttast to the highly 
sedative diphenhydramine which has a log P of 1.76 (pH 7.4). Terfenadine and loratadine, both 
classified as nonsedating, may be examples of antihistamines with very low CNS entry because of 
their highly hydrophobic nature (log P values of > 4.00 and 5.37, respectively at pH 7.4). 
Pirenzepine (4) is an antiulcer agent with overall structural features that resemble the tricyclic 
psychotropic drugs. However, it has a log P of -0.64 (pH 7.4) and consequently is devoid of CNS 
side effects [28]. A promising cardiotonic drug ARL 57 (5, X = OCH3) with a log P of 2.59 (pH 
8) had to be abandoned because of CNS-related side effects in humans. However, replacement of 
an - OCH3 group b y -  SOCH3 (ARL 115, sulmazole; 5, X = SOCH3) reduced the log P to 1.17 
(pH 8), while maintaining adequate cardiotonic properties with virtual elimination of the CNS- 
related side effects [29]. 
Lovastatin and simvastatin, HMG-CoA reductase inhibitors in clinical use for hyperchol- 
esterolemia with log Ps (pH 7) of 1.70 and 2.06 respectively, have both been observed to cause 
significant reduction in the duration of sleep in some patients while pravastatin 0og P = -0.23 at 
pH 7) had no effect on sleep patterns [30]. This represents yet another example of the same 
phenomenon which can be used to advantage in drug design. 
An interesting study by Young et al. [31], published in 1988 on the design of centrally acting H2 
receptor antagonists, showed an excellent correlation of log brain/blood concentration ratios in 
rat and the partition parameter, A log P, defined as log P ~  - log Poycloh ...... for a group of six 
compounds consisting of the three brain-penetrating drugs clonidine, mepyramine and imipra- 
mine, and three typical H 2 receptor antagonists. On the other hand, there was no correlation with 
log Poct for the neutral compounds. The result was interpreted as suggesting that brain penetra- 
tion is increased by lowering the overall hydrogen-bonding ability of a compound, which enhan- 
ces its ability to cross cell membranes. The study was subsequently expanded to cover 20 structur- 
ally diverse compounds which confirmed the initial results. One of the compounds, zolantidine 
(SK&F 95282) was identified for use in studying histaminergic H 2 receptor mechanisms in brain. 
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A subsequent study of this concept by Van de Waterbeemd and Kansy [32] on the same two 
compound sets showed that it is only necessary to measure log P in an atkane solvent and that a 
first estimate of brain penetration can even be obtained from calculated hydrophilic and hydro- 
phobic surface contributions of the molecules. Clearly, further investigation of A log P in relation 
to CNS penetration is warranted. 
Pharmacokinetie considerations 
A successful drug candidate must have favorable pharmacokinetic properties relating to 
absorption, distribution, metabolism and excretion, which all have hydrophobicity as a critical 
determining factor. Such relationships have been examined in a QSAR context for many series of 
compounds and have been reviewed by Austel and Kutter [33] and by Lien [34]. Absorption from 
the gastrointestinal tract generally shows a parabolic relationship with log P and an optimal range 
for log P (or log D for ionizable compounds) of 0.5-2.0. For buccal and percutaneous absorption 
the optimum log P is much higher. The optimum hydrophobicity for distribution of a drug to 
many parts of the body may be at a log P of around 2 [35]. Metabolism by microsomal oxidation 
tends to increase with log P, although this is somewhat series dependent. Protein binding is 
positively correlated with log P in a linear form, often up to log P values of 3 or higher. Hydro- 
philic compounds with molecular weight less than 500 tend to undergo fairly rapid renal excretion 
and have a short duration of action. 
Sometimes QSAR studies can identify an area of a molecule that is not important for the 
desired pharmacological activity. This area can then be used to modify the pharmacokinetic or 
physicochemical properties, such as solubility, without impacting activity. An example is provid- 
ed by a QSAR analysis of a series of fifty-six 8-phenylxanthines which were of interest as ade- 
nosine antagonists [36]. The resulting QSAR showed that potency was relatively insensitive to 
changes in the para position of the phenyl substituent. On this basis an additional 20 compounds 
were synthesized that contained mostly para substituents, designed to increase aqueous solubility. 
These were highly potent receptor binders, as predicted by the QSAR, and aqueous solubility was 
dramatically increased. 
General considerations 
The log Po value obtained from QSAR studies has proved to be useful in providing drug design 
concepts and has already been discussed in this article with regard to CNS penetration and drug 
absorption. Early in the development of QSAR, log Po values were shown to be much lower for 
activity against gram-negative compared to gram-positive bacteria, which is consistent with the 
observation that the gram-negative cell wall contains more lipid and hence may be relatively more 
effective in slowing down the passage of highly lipophilic molecules [37]. Of importance in 
antitumor drug design [38] is that log Po can be expected to be quite different for different tumor 
types, e.g. log Po = 0 for N-nitrosoureas against ascitic tumors, whereas solid tumors such as 
Walker 256 respond to more lipophilic drugs with a log Po of about 2. 
In correlations of drug potency in whole animals the log P term reflects a composite of various 
processes such as absorption, distribution, protein binding, metabolism, excretion and hydro- 
phobic bonding at the target receptor. The log Po value for each compound series will differ, 
depending on the relative importance of all these processes. 
In drug discovery projects involving in vitro test systems, e.g. enzyme inhibitors, it is important 
0 0 OH OH 
x 
~ (6) (7) 
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not to pursue potency increases in a compound series to very high levels through large increases 
in hydrophobicity, which can often be achieved when there is a large hydrophobic binding pocket. 
This might result in compound log P values well above the range necessary for optimal in vivo 
activity. Also the advantages of keeping drug hydrophobicity to the lowest value consistent with 
achieving the necessary drug effectiveness and property profile has been discussed by Hansch 
who pointed out that toxicity tends to increase as drugs become more hydrophobic [27]. 
POTENCY OPTIMIZATION 
Impressive examples of the use of QSAR in dramatically increasing potency in a series have 
been reported by Wooldridge [39] for a series of 2-phenyl-8-azapurin-6-ones (6) and by Cramer 
[40] for a series of pyranenamines (7), both relating to antiallergic activity as measured by rat 
PCA activity. These have been reviewed in detail elsewhere [41] and involve potency enhance- 
ments of up to 1000-fold, extending far beyond the substituent space spanned (SSS) in the initial 
QSAR relationships. Features of the Wooldridge studies are the identification of a clinically 
active compound, M&B 22,948 (zaprinast), intermingling of QSAR and traditional medicinal- 
chemistry approaches and the projection of the results to structures completely different from 
those which formed the basis of the QSAR studies. Noteworthy aspects of the Cramer work are 
the productive use of a simple graphical data/parameter display as well as regression analysis in 
identifying the key requirements for increased potency (greater hydrophilicity and a zero elec- 
tronic effect) which were not obvious, justification for the synthesis of a compound with a novel 
hydrophilic substituent (7; X,Y = 3,5-NHCOCH(OH)CH2OH) which was the most potent in a 
series of 98 compounds, and a series member (X = 3-NH2,  Y = 4-OH) which entered clinical trials. 
Both compound series require very hydrophilic compounds for maximum potency, which might 
have more general implications for this type of activity. 
A more recent example was described by de Paulis et al. [42] where a QSAR analysis resulted 
in the design and synthesis of a new 10-fold more active derivative (8; R2 = R3 = OCH3, R5 -= Br, 
16 0 
R4 R 2 
R3 
N " ~ N ~ C H  2 - 0  (8) 
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R 6 = OH) in a series of antidopaminergic N-(1-benzyl-4-piperidinyl)salicylamides. Increased 
potency, as measured by affinity for the [3H]spiperone binding site, was correlated with electron 
release into the salicylamide ring from positions 3, 4 and 5 as parametrized by the Swain-Lupton 
resonance constant R and the presence of a 6-OH substituent. Again, in this example the success- 
ful prediction of increased potency extended far beyond the SSS of the compound set on which the 
QSAR was formulated. Generally the predictive reliability of QSARs under these circumstances 
is not high, but the three examples described show that the testing of such predictions can be very 
rewarding. They also illustrate a great strength of classical QSAR, in that correlations with 
physicochemical parameters can be easily interpreted and successfully extrapolated in the design 
of new compounds. In contrast, the interpretation and use of correlations involving nonphysico- 
chemical parameters (e.g. molecular connectivity indices) is generally much more difficult. 
BIOISOSTERISM 
Bioisosterism has long been used by medicinal chemists in drug design in exploring the effect 
of substituting one atom or grouping for another in a lead compound. It has been defined in a 
QSAR context by Hansch [12,43]. If in a particular series activity is solely dependent on :~, then 
any two substituents with very similar ~ values will be bioisosteric. If both rc and (y (or F and R) 
control activity, then groups for which these values are essentially the same are considered to be 
bioisosteric. In the case where ~, (~ and Es all have a role in activity determination, the two groups 
are considered to be bioisosteric if all of the parameter values match. 
In a very recent application [44] this concept of bioisosterism provided the impetus for the 
novel replacement of a chloro substituent (~ = 0.71, F = 0.41, R = -0.15) by a 1-pyrrolyl 
substituent (~ = 0.95, F = 0.50, R = -0.09) in an antihypertensive AII receptor antagonist lead 
series (9) with retention of activity. This led to the synthesis of a closely related compound (9, 
X = 2-triftuoroacetyl-[1-pyrrolyl]) (CI-996) which was selected for prectinical development. 
In addition to parameter values representing hydrophobic, electronic and steric effects, other 
physicochemical properties can also be considered in bioisosteric replacements. Durant et al. [45] 
noted a close similarity in the physicochemical properties of cyanoguanidines and thioureas in 
terms of N - C - N  geometry, acidity, hydrophobicity and conformer interconversion energies. This 
formed the basis of the thiourea group replacement in the H2-antagonist compound metiamide, 
which had encountered toxicity problems, by a cyanoguanidine group, resulting in the break- 
through drug cimetidine. 
X = C I  N~N", NH 
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The fact that QSAR is based on readily understandable physicochemical phenomena often 
permits useful mechanistic insights. Tute [46] has termed this the diagnostic value of Hansch 
analysis. Well-known examples are the antifungal drug griseofulvin, where a QSAR analysis of 
analogs suggested that activity may depend on the reactivity of the enone system with a receptor 
nucleophile [47], and the tuberculostatic drug isoniazid where QSAR studies supported quaterni- 
zation of the pyridine nitrogen as the rate-determining step in the mechanism of antibacterial 
action [48]. Also in a recent study of antiinflammatory dMofenac analogs [49], inhibition of 
cyclooxygenase activity and adjuvant-induced arthritis in rats were similarly correlated with 
hydrophobicity and the twist angle between the two phenyl rings as the critical parameter control- 
ling activity, which is supportive of cyclooxygenase inhibition as the underlying mechanism for 
the antiinflammatory activity of the compounds. 
SYNTHESIS TERMINATION 
One of the most difficult decisions a medicinal chemist faces is when to terminate synthesis in 
a series. QSAR can be helpful in this respect. For example, for a nine-membered series of nitrogen 
mustard anticancer agents [50] QSAR equations derived for activity and toxicity were identical and so 
there is no realistic prospect of significant selectivity improvement in the series. A similar situation 
existed for a series of anticancer triazines [51], where both activity and toxicity correlated with a 
- ~  term. QSAR studies have also provided a convincing rationale for terminating synthesis in 
series of anticancer anthracyclines [52], anticancer colchicines [53], antiinflammatory agents [54], 
antibacterial triazines [55], erythromycin analogs [56] and xanthine adenosine antagonists [36]. 
RECEPTOR MAPPING 
Information on receptor sites and the nature of receptor-ligand interactions can be deduced 
from QSAR studies. This can be most readily accomplished with enzymes, sometimes in conjunc- 
tion with X-ray crystallographic studies and molecular graphics [57]. An extensively investigated 
and welt-reviewed subject has been the enzyme dihydrofolate reductase (DHFR), inhibitors of 
which have been the source of antibacterial, antimalarial and antineoplastic agents. A recent 
publication reported the use of QSAR equations for bacterial and avian DHFR to calculate 
selectivity indices for trimethoprim, tetroxoprim and two other specially designed 2,4-diamino-5- 
(substituted-benzyl)pyrimidines, reflecting subtle enzyme-binding differences revealed by the 
QSAR studies [58]. 
A QSAR study of the binding of a series of Nl-substituted 5-aryl-2,4-dioxopyrimidines (10) to 
thymidylate synthase supported the presence of both a cationic binding site and a hydrophobic 
region and in addition revealed an unusual reversal of electronic requirements for binding and 
catalysis [59]. QSAR equations formulated for the inhibition of HSV1 and HSV2 thymidine 
kinases by a series of N-phenylguanines (11) have provided insight into the nature of inhibitor 
binding sites for both enzymes. For compounds with meta substituents on the phenyl ring, 
binding of both enzymes is due to a combination of hydrophobic and electrostatic interactions, 











deduced that the space into which the para substituents fit is electrostatic in nature and possibly 
hydrophilic [60]. The receptor mapping of N1 substituents of quinolone antibacterials using a 
combination of QSAR and molecular modeling studies has been recently reported. In this model, 
compounds mispredicted by previous QSAR studies are accounted for [61]. A variety of nonen- 
zyme receptor models have also been constructed based on QSAR studies. These models can be 
very useful in guiding synthetic efforts in the search for improved compounds. 
EXAMPLES OF THE FREE-WILSON APPROACH 
The Free-Wilson method (usually implemented as the Fujita-Ban modification) has been 
employed far less frequently than the Hansch method, primarily because the derived de novo 
constants give no indication of which physicochemical property or combination of properties is 
controlling activity and therefore the results cannot be projected to new substituents. However, 
the method has yielded some useful results, as illustrated by two recent examples. 
In an analysis of the analgesic potency of some 50 semisymhetic opioid narcotics, a satisfactory 
correlation was obtained only by assuming interdependent contributions of substituents at two 
positions. The correlation enabled the potency of five substituted compounds to be predicted and 
subsequent testing showed these predictions to be accurate. A further analysis, in which phenolic 
compounds were considered separately from the ethers, allowed the conclusion that if both 
phenolic and nonphenolic members of the series act on the same receptor, they must bind at 
different subsites or in alternate modes [62]. 
A series of 36 dipeptoid antagonists of the CCK-B receptor was analyzed by considering the 
compounds as composed of three regions; the N-terminus, variants on the tryptophan moiety and 
the C-terminus. A highly significant correlation was found, accounting for 97% of the data 
variance, which suggested that the three domains of the compounds independently contribute to 
binding affinity and are thus additive in receptor binding affinity effects. It was calculated that 
substitution of D-o~-methyltryptophan for L-tryptophan increases the free energy of binding by 
3.5 kcal mo1-1 which is explained by a 300-fold difference in conformational entropy between 
these two analogs [63]. 
THE ROLE OF QSAR IN THE DESIGN OF MARKETED DRUGS AND LATE-STAGE 
D R U G  CANDIDATES 
One measure of the impact of classical QSAR is its role in the design of compounds which reach 
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a late investigational stage or are marketed. A brief mention of some examples of these follows. 
Quinolones are an important class of antibacterial agents. The research efforts of Koga [64] in 
this field to develop new improved drugs made extensive use of QSAR and culminated in the 
design of nortloxacin (12), now an important and well-established marketed drug. A detailed 
review of this work has been provided by Fujita [41]. 
A comprehensive program on the design and synthesis of over 700 acridines (DNA binders) as 
potential anticancer agents in which QSAR studies played an important role was carried out at 
the Cancer Chemotherapy Research Laboratory in Auckland, New Zealand, by Atwell et al. who 
very early in their investigations recognized the importance of relative hydrophobicity [65]. A 
QSAR relationship on 509 acridines was formulated with a log P = -0.6, which is consistent with 
that for other antileukemic drugs. The outcome of this research was the selection of the com- 
pound m-AMSA for clinical trials, which is now marketed as the drug amsacrine (13). 
The use of a nonstatistical operational scheme [5] was reported in the design of 3-amino-1- 
benzylpyrazolin-5-ones, a class of potent high-ceiling diuretics [66]. This work resulted in the 
development of muzolimine (14) which is now a marketed drug. 
Cimetidine (15) is a highly successful antiulcer drug and its design from metiamide has been 
described in the section on bioisosterism. Since the rationale for its synthesis involved a quantita- 
tive comparison of physicochemical properties, it qualifies for inclusion here under a broad 
definition of classical QSAR. 
An account of two allergy drugs which reached the clinical-trial phase, zaprinast and a pyra- 
nenamine, in which QSAR studies featured prominently, has been given in the section on potency 
optimization. Also, the key role of QSAR in the discovery of the cardiotonic drug sulmazole, 
which underwent clinical trials, was described (vide supra). 
The QSAR-directed design of a nondepressive cardioselective [3-blocker which reached the 
clinical-investigation stage, RS-51288, containing a novel endobicyclo[3.1.0]hexylethyl (EBHE) 
side chain, has been reported by Unger [67]. Fujita [41] has given detailed reviews of several 
CI NCN H2N. ,, 
CI H 3 C ~  CH2SCH2CH2NHCNHCH3 
HN ,,,,~N 
o (14) (15) 
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QSAR-driven design projects which yielded compounds reaching advanced stages of investiga- 
tion. These were a benzodiphenylmethylpiperazine cerebral vasodilator, KB-2796, which entered 
clinical studies, a 4-anilinopyrimidine antidepressant, RS-2232, a quinazoline antihypertensive, 
MY-5561, and a furoindolecarboxamide with analgesic/antiinflammatory activity, all of which 
reached an advanced preclinical stage of investigation. As previously discussed under Bioisoster- 
ism, the AII antagonist antihypertensive CI-996, arising from a novel bioisosteric replacement, 
was selected for preclinical development. 
SOME INTERESTING RECENT QSAR STUDIES 
A novel concept was developed as a result of studies on antineoplastic agents in multidrug 
resistance, which illustrates how QSAR can stimulate new thinking. It was found that cross- 
resistance of actinomycin-D-resistant Chinese hamster cells was enhanced by both the increased 
size and hydrophobicity of the antitumor agent. Preliminary studies with methotrexate-resistant 
L 1210 cells indicated that cross-resistance is increased in the case of moderate-sized hydrophilic 
drugs. As a result of these and other studies it was concluded that current chemotherapy regimens 
may be improved by treating resistant cells with antineoplastic agents displaying physicochemical 
characteristics opposite to those of the original inducing agent [68]. 
In the first reported successful QSAR analysis involving in vivo activity of a compound against 
solid tumors, Schnurr et al. [69] reported the synthesis and QSAR analysis of a series of guanidi- 
nothiazole carbox~tmides (16) which show significant systemic activity for survival enhancement 
of mice with established micrometastatic disease of 3LL Lewis lung carcinoma. Optimal correla- 
tions were found in the case of 5- and 6-substitution between the probit transfolan of the drug- 
induced increased lifespan (ILS) and electronic and hydrophobic parameters. No correlations 
were found for 4-substitution. In general, activity increased with increased hydrophobicity but, 
judging by the parameter coefficients, the electron-withdrawing effect of a substituent had a 
greater influence on activity. The optimum hydrophobicity for the series appeared to be above the 
range encompassed by the analogs reported in the study. As discussed by the authors, there are 
limitations and advantages to this type of QSAR study. A limitation is the time and expense 
required to adequately quantify the biological data for all the compounds in the study with the in 
vivo antitumor testing requiring a minimum of 10-20 days. Also, the analogs must be relatively 
homogeneous with regard to other pharmacologic and metabolic properties, in addition to pos- 
sessing significant antitumor effects. However, the developing QSAR was useful in formulating 
the synthetic strategy leading to the discovery of the optimal analogs as well as indicating where 
an empirical approach was best. The end result was the discovery of a number of promising 
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compounds, exemplified by 16, R = 5-F, with substantial efficacy in the clinically predictive 
model of 3LL Lewis lung carcinoma. 
The first QSAR analysis accounting for the variation in activity of phencyclidine (PCP) deriva- 
tives (17), expressed as receptor binding activity,, has been reported [70]. This result was also 
unusual in that the activity of the series of 24 compounds was well correlated (r = 0.913), with a 
single parameter representing the difference in direction of the dipole vector. This was interpreted 
in terms of the favorable effects on activity of the complementarity of charge densities around the 
molecule and the receptor cavity, with the dipole-moment term representing the electrostatic 
distribution of the molecule. 
A report by Morris et al. [71] on the design of some novel nonsteroidal antiandrogens nicely 
illustrates yet another way in which the quantitative correlation of biological activity with phys- 
icochemical properties can be put to effective use in drug design, through the unraveling of the 
essential factors governing activity. This study on the physicochemical requirements for anti- 
androgenic activity in a series of 2-hydroxypropionanilides (18) showed that a single dominant 
conformation has an important influence on the ability of the -OH group to act as a hydrogen- 
bond donor. The strength of the hydrogen bond to an external acceptor was shown to be an 
important factor controlling the biological activity of the compounds. These and other physico- 
chemical parameters were then used in the design of structurally novel antiandrogens (19, 20) 
which exhibited the anticipated activity. 
CONCLUDING OBSERVATIONS 
The utility and scope of classical QSAR in many facets of drug design has been amply demon- 
strated in the three decades since its inception. During this time it has passed through various 
stages: method development, exploration of applications, user overenthusiasm followed by skep- 
ticism, to a point where its strengths, limitations and the types of problems to which it might be 
fruitfully employed are well understood. 
As with any approach, certain limitations must be recognized which for classical QSAR include 
the need to discern the molecular properties that control activity and to express these in parame- 
ter form, the inadequate treatment of three-dimensional aspects, and restricted applicability 
beyond the confines ofa  cogeneric series. However, QSAR is readily comprehended and relative- 
ly easy to use, since the principles on which it is based are very familiar to medicinal chemists. 
Therefore, in the realm of drug design methodology it frequently has a favorable benefit/resource 
investment relationship. 
Classical QSAR has been successfully integrated with molecular graphics and molecular mod- 
eling and very recently [72] with the Comparative Molecular Field Analysis (CoMFA) methodol- 
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ogy. Hansch [35] has commented on an increasing future emphasis on the lateral validation of 
QSAR, i.e. placing a new QSAR into a matrix of structure-activity relationships which are 
selfconsistent both from the point of view of physicochemical parameters and basic biochemistry. 
Classical QSAR is solidly established as a core methodology and over the next decade we can 
expect further refinements, interfacing with other drug design approaches, and diverse productive 
applications to drug design problems. 
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